The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

The program originated from a joint venture between Rallybio and Recursion focused on discovering and developing novel, orally available small-molecule inhibitors of ENPP1 for HPP patients. Recursion ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More Published ...

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug discovery for various indications across different disease areas. They ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal ...

REC-3964 is the first novel small molecule developed through Recursion’s Operating System, and selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff in the ...

Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in ...

Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in ...